163 related articles for article (PubMed ID: 34825020)
1. Hypercalcemia following discontinuation of denosumab therapy: A systematic review.
Horiuchi K; Kobayashi E; Mizuno T; Susa M; Chiba K
Bone Rep; 2021 Dec; 15():101148. PubMed ID: 34825020
[TBL] [Abstract][Full Text] [Related]
2. Osteonecrosis of the Jaw and Rebound Hypercalcemia in Young People Treated With Denosumab for Giant Cell Tumor of Bone.
Uday S; Gaston CL; Rogers L; Parry M; Joffe J; Pearson J; Sutton D; Grimer R; Högler W
J Clin Endocrinol Metab; 2018 Feb; 103(2):596-603. PubMed ID: 29211870
[TBL] [Abstract][Full Text] [Related]
3. Severe hypercalcemia following denosumab treatment in a juvenile patient.
Setsu N; Kobayashi E; Asano N; Yasui N; Kawamoto H; Kawai A; Horiuchi K
J Bone Miner Metab; 2016 Jan; 34(1):118-22. PubMed ID: 26056018
[TBL] [Abstract][Full Text] [Related]
4. Hypercalcemia after discontinuation of long-term denosumab treatment.
Koldkjær Sølling AS; Harsløf T; Kaal A; Rejnmark L; Langdahl B
Osteoporos Int; 2016 Jul; 27(7):2383-2386. PubMed ID: 27098536
[TBL] [Abstract][Full Text] [Related]
5. Hypercalcemia upon denosumab withdrawal in primary hyperparathyroidism: a case report and literature review.
Camponovo C; Aubry-Rozier B; Lamy O; Gonzalez Rodriguez E
Osteoporos Int; 2020 Dec; 31(12):2485-2491. PubMed ID: 33057735
[TBL] [Abstract][Full Text] [Related]
6. Critical hypercalcemia following discontinuation of denosumab therapy for metastatic giant cell tumor of bone.
Gossai N; Hilgers MV; Polgreen LE; Greengard EG
Pediatr Blood Cancer; 2015 Jun; 62(6):1078-80. PubMed ID: 25556556
[TBL] [Abstract][Full Text] [Related]
7. Denosumab-Induced Rebound Hypercalcemia Treated With Bisphosphonates in a Pediatric Patient.
Gandolfi A; Shaaban S
JCEM Case Rep; 2023 Sep; 1(5):luad133. PubMed ID: 37908209
[TBL] [Abstract][Full Text] [Related]
8. Denosumab: an Emerging Therapy in Pediatric Bone Disorders.
Boyce AM
Curr Osteoporos Rep; 2017 Aug; 15(4):283-292. PubMed ID: 28643220
[TBL] [Abstract][Full Text] [Related]
9. Denosumab in pediatric bone disorders and the role of RANKL blockade: a narrative review.
Wang D; Tang X; Shi Q; Wang R; Ji T; Tang X; Guo W
Transl Pediatr; 2023 Mar; 12(3):470-486. PubMed ID: 37035391
[TBL] [Abstract][Full Text] [Related]
10. Elevated levels of circulating fibroblast growth factor 23 with hypercalcemia following discontinuation of denosumab.
Uchida T; Yamaguchi H; Kushima C; Yonekawa T; Nakazato M
Endocr J; 2020 Jan; 67(1):31-35. PubMed ID: 31527321
[TBL] [Abstract][Full Text] [Related]
11. Discontinuation of Denosumab therapy for osteoporosis: A systematic review and position statement by ECTS.
Tsourdi E; Langdahl B; Cohen-Solal M; Aubry-Rozier B; Eriksen EF; Guañabens N; Obermayer-Pietsch B; Ralston SH; Eastell R; Zillikens MC
Bone; 2017 Dec; 105():11-17. PubMed ID: 28789921
[TBL] [Abstract][Full Text] [Related]
12. Acute hypercalcemia and excessive bone resorption following anti-RANKL withdrawal: Case report and brief literature review.
Roux S; Massicotte MH; Huot Daneault A; Brazeau-Lamontagne L; Dufresne J
Bone; 2019 Mar; 120():482-486. PubMed ID: 30572144
[TBL] [Abstract][Full Text] [Related]
13. Aneurysmal bone cyst: results of an off label treatment with Denosumab.
Dürr HR; Grahneis F; Baur-Melnyk A; Knösel T; Birkenmaier C; Jansson V; Klein A
BMC Musculoskelet Disord; 2019 Oct; 20(1):456. PubMed ID: 31630689
[TBL] [Abstract][Full Text] [Related]
14. Denosumab treatment for fibrous dysplasia.
Boyce AM; Chong WH; Yao J; Gafni RI; Kelly MH; Chamberlain CE; Bassim C; Cherman N; Ellsworth M; Kasa-Vubu JZ; Farley FA; Molinolo AA; Bhattacharyya N; Collins MT
J Bone Miner Res; 2012 Jul; 27(7):1462-70. PubMed ID: 22431375
[TBL] [Abstract][Full Text] [Related]
15. Denosumab: a new agent in the management of hypercalcemia of malignancy.
Thosani S; Hu MI
Future Oncol; 2015; 11(21):2865-71. PubMed ID: 26403973
[TBL] [Abstract][Full Text] [Related]
16. Successful denosumab treatment for central giant cell granuloma in a 9-year-old child.
Mariz BALA; Migliorati CA; Alves FA; Penteado FM; Carvalho NP; Santos-Silva AR; Rocha AC
Spec Care Dentist; 2021 Jul; 41(4):519-525. PubMed ID: 33760257
[TBL] [Abstract][Full Text] [Related]
17. Denosumab in hypercalcemia of malignancy: a case series.
Dietzek A; Connelly K; Cotugno M; Bartel S; McDonnell AM
J Oncol Pharm Pract; 2015 Apr; 21(2):143-7. PubMed ID: 24415364
[TBL] [Abstract][Full Text] [Related]
18. Mechanisms of acute hypercalcemia in pediatric patients following the interruption of Denosumab.
Deodati A; Fintini D; Levtchenko E; Rossi M; Ubertini G; Segers H; Battafarano G; Cappa M; Del Fattore A
J Endocrinol Invest; 2022 Jan; 45(1):159-166. PubMed ID: 34216372
[TBL] [Abstract][Full Text] [Related]
19. Challenges of denosumab in giant cell tumor of bone, and other giant cell-rich tumors of bone.
Lipplaa A; Dijkstra S; Gelderblom H
Curr Opin Oncol; 2019 Jul; 31(4):329-335. PubMed ID: 30844887
[TBL] [Abstract][Full Text] [Related]
20. Denosumab for craniofacial fibrous dysplasia: duration of efficacy and post-treatment effects.
Raborn LN; Burke AB; Ebb DH; Collins MT; Kaban LB; Boyce AM
Osteoporos Int; 2021 Sep; 32(9):1889-1893. PubMed ID: 33772327
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
